Florida Patent of the Month – June 2023
Vector Vitale IP, LLC was founded to develop a breakthrough class of therapeutic solutions which re-balance biomolecules in our bodies. The company’s technology is based on the concept of treating infections with specific isotopes.
An isotope is a single member of a family of an element, where all isotopes have the same number of protons but a different number of neutrons. While isotopes have similar chemical properties, this slight deviation can greatly impact physical properties. Studies have shown that the isotopic composition of tissue can serve as a diagnostic marker.
Deviations from our natural state, such as an increase or decrease in specific isotope abundance, may impact our immune systems. Vector Vitale’s recent patent uses this concept, offering a novel antibacterial composition enriched with light isotopes of chemical elements to restore our immune system.
The inventors believe that heavy isotopes, which accumulate in the body over time, cause a decline in health and functionality of proteins and other molecules. By restoring the body’s original isotope relative abundances or moving them back in the natural direction, this decline can be countered. Moreover, it has been discovered that pathogenic bacteria can be suppressed by treating them with light isotopes of certain elements, altering the chirality of their autocatalytic products and leading to their death or suppressed growth. Hence, treatment with light isotopes can enhance the body’s ability to fight bacterial infections while simultaneously eradicating the infective bacteria.
The company’s initial application of their breakthrough technology is focused on the treatment of solid malignant tumors, diabetes, obesity, and Parkinson’s disease. Their KLS-1 candidate is currently in Phase 1 with a First-in-Human Dose escalation and expansion study in patients with cancer and neurodegenerative diseases.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
